ANG Lifesciences India Ltd

ANG Lifesciences India Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company has advised all designated persons and their immediate relatives not to trade in its securities during this period, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The date of the board meeting to consider these financial results will be intimated separately.

ANG Lifesciences India Ltd. announced audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved these results on May 30, 2026, following a review by the Audit Committee. The company's revenue from operations for the year ended March 31, 2026, stood at ₹9,160.45 lakhs compared to ₹8,991.01 lakhs in the previous year. The company reported a profit after tax of ₹110.25 lakhs for the quarter ended March 31, 2026.

ANG Lifesciences India Ltd has announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. Key figures from the standalone results include revenue from operations of ₹9,160.45 lakhs for the year ended March 2026, compared to ₹8,991.01 lakhs in the previous year. The company reported a profit of ₹110.25 lakhs for the year, a significant decrease from the previous year's loss of ₹1,034.29 lakhs. The board meeting, where the results were approved, commenced at 5:00 PM and concluded at 09:50 PM on May 30, 2026.

ANG Lifesciences India Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The trading window is closed from April 1, 2026, and will reopen 48 hours after the results are made public.

ANG Lifesciences India Ltd responded to an email from BSE Limited dated April 09, 2026, seeking clarification regarding a significant movement in the company's share price. The company informed BSE that there is no additional price-sensitive information or announcement that, in its opinion, could have influenced the price/volume behavior of its scrip. ANG Lifesciences stated that the movement in price is purely market-driven, and the company has no control over or knowledge of such factors. The company also reiterated its commitment to regularly disseminating all required price-sensitive information and disclosures in accordance with SEBI regulations.

ANG Lifesciences India Ltd has announced the closure of its trading window for dealing in the securities of the company. The closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's code of conduct. The trading window will be closed for the insider, designated persons of the company and their immediate relatives from April 1, 2026 until 48 hours after the declaration of the Audited Standalone and Consolidated Financial Results for the quarter and year ending 31 March, 2026. The date of the Board Meeting for consideration of these results will be intimated separately.

ANG Lifesciences India Ltd has approved the Standalone & Consolidated Un-Audited Financial Results for the quarter and nine months ended on December 31, 2025. The approval was given in a Board of Directors meeting held on February 14, 2026. The financial results were reviewed by Khurana Sharma & Co., the Statutory Auditors of the Company.

ANG Lifesciences India Ltd has reported its unaudited financial results for the quarter and nine months ended on 31 Dec, 2025. The company's revenue from operations for the nine-month period stood at ₹ 6,880.44 lakhs, with a net loss of ₹ 1,034.29 lakhs. The company's standalone and consolidated financial results were approved in a board meeting on 14 Feb, 2026. Khurana Sharma & Co., the statutory auditors, issued a limited review report on the financial results.

ANG Lifesciences India Ltd. has announced that its Board of Directors will meet on February 14, 2026, to consider and approve the Standalone and Consolidated Un-Audited Financial Results for the quarter and nine months ended 31 December, 2025. The meeting will be held at the company's registered office in Amritsar. The trading window for insider trading will be closed from January 1, 2026, and will reopen 48 hours after the results are made public on February 14, 2026.

ANG Lifesciences India Ltd has announced the closure of its trading window in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The closure is effective from 1st January 2026 for the company's insiders, designated persons, and their immediate relatives. The trading window will reopen 48 hours after the declaration of the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ending 31st December 2025. The date of the Board Meeting for the consideration of these financial results is yet to be announced.